Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-426: Pembrolizumab + Axitinib vs Sunitinib in First-line Metastatic RCC
2023-507294-18-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Pembrolizumab + Axitinib with Sunitinib monotherapy (2 arms). Primary endpoints: Progression-Free Survival (PFS) and Overall Survival (OS). Started Dec 2023; status: completed.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2023-507294-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507294-18-00.